Accuray Incorporated (ARAY)

Market Cap	256.27M
Revenue (ttm)	455.00M
Net Income (ttm)	-6.80M
Shares Out	97.07M
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	537,746
Open	2.61
Previous Close	2.64
Day's Range	2.61 - 2.77
52-Week Range	1.85 - 4.30
Beta	1.55
Analysts	Strong Buy
Price Target	7.50 (+172.73%)
Earnings Date	Nov 7, 2023

About ARAY

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney,...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 8, 2007
• Employees: 1,024
• Stock Exchange: NASDAQ
• Ticker Symbol: ARAY

Financial Performance

In 2023, Accuray's revenue was $447.61 million, an increase of 4.12% compared to the previous year's $429.91 million. Losses were -$9.28 million, 73.6% more than in 2022.

Analyst Forecast

According to one analyst, the rating for ARAY stock is "Strong Buy" and the 12-month stock price forecast is $7.5.

Price Target

$7.5

(172.73% upside)

Analyst Consensus: Strong Buy